Therapeutic Asset Ratings
141 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
bnt141
Metastatic Cancer
BioNTech SE
P1/2
CC
(43)
Cjrb-101
Metastatic Cancer
CJ Bioscience, Inc.
P1/2
CC
(43)
Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301)
Metastatic Cancer
Washington University School of Medicine
P1/2
CC
(43)
Defactinib
Metastatic Cancer
Verastem, Inc.
P1/2
CC
(43)
Fog-001
Metastatic Cancer
Parabilis Medicines, Inc.
P1/2
CC
(43)
Hbi 0201-Eso Tcrt
Metastatic Cancer
Hadassah Medical Organization
P1/2
CC
(43)
INX315
Metastatic Cancer
Incyclix Bio
P1/2
CC
(43)
jk08
Metastatic Cancer
Salubris Biotherapeutics Inc
P1/2
CC
(43)
or502
Metastatic Cancer
OncoResponse, Inc.
P1/2
CC
(43)
PSMA I&T
Metastatic Cancer
CHU de Quebec-Universite Laval
P1/2
CC
(43)
q901
Metastatic Cancer
Qurient Co., Ltd.
P1/2
CC
(43)
Rezatapopt
Metastatic Cancer
PMV Pharmaceuticals, Inc
P1/2
CC
(43)
Solnerstotug
Metastatic Cancer
Sensei Biotherapeutics, Inc.
P1/2
CC
(43)
TIPIRACIL
Metastatic Cancer
Parabilis Medicines, Inc.
P1/2
CC
(43)
Trifluridine
Metastatic Cancer
Parabilis Medicines, Inc.
P1/2
CC
(43)
xon7
Metastatic Cancer
Xenothera SAS
P1/2
CC
(43)
Zovostotug
Metastatic Cancer
OncoResponse, Inc.
P1/2
CC
(43)
art4215
Metastatic Cancer
Artios Pharma Ltd
P1
CC
(42)
Bendamustine
Metastatic Cancer
Fred Hutchinson Cancer Center
P1
CC
(42)
Dostarlimab
Metastatic Cancer
University of Washington
P1
CC
(42)
Evorpacept
Metastatic Cancer
QuantumLeap Healthcare Collaborative
P1
CC
(42)
Hmbd-002
Metastatic Cancer
Hummingbird Bioscience
P1
CC
(42)
snk02
Metastatic Cancer
NKGen Biotech, Inc.
P1
CC
(42)
Zofran
Metastatic Cancer
Fred Hutchinson Cancer Center
P1
CC
(42)
Camonsertib
Metastatic Cancer
Memorial Sloan Kettering Cancer Center
P1/2
CC
(41)
Showing 76 to 100 of 141 assets
Previous
Page 4 of 6
Next
